Target intelligence / Profile preview

Natural killer cell receptor system (NKG2D and KIR) (NKRs)

Target
NKRs
Molecular classification
Receptor, Cell surface protein, Immunoglobulin superfamily, C-type lectin-like receptor
01

Overview

The Natural killer (NK) cell receptor system is a complex network of activating and inhibitory receptors that mediate the recognition of malignant cells (Vivier et al., Science 2011). This system primarily involves the recognition of "stress-induced" ligands, such as MICA and MICB, by the activating receptor NKG2D (KLRK1), and the "missing-self" mechanism, where the absence of Major Histocompatibility Complex (MHC) class I molecules triggers NK cell activation by relieving inhibition from Killer-cell Immunoglobulin-like Receptors (KIRs) (Shimasaki et al., Nat Rev Drug Discov 2020). These interactions are central to the Reactome pathway "Cancer-cell-associated stress and 'missing-self' ligands recognized by autologous NK/NKT cell receptors" (R-HSA-1236394). In cancer, the balance of these signals is often disrupted, allowing tumors to evade immune surveillance despite the presence of stress ligands. Therapeutic interventions like monalizumab and lirilumab target these pathways by blocking inhibitory receptors (NKG2A and KIR, respectively) to restore NK cell effector functions (André et al., Cell 2018). Additionally, NKG2D-based chimeric antigen receptor (CAR) therapies are being developed to exploit the broad expression of stress ligands on various solid and hematological tumors. Clinical challenges include the shedding of soluble ligands by tumor cells, which can act as decoys and impair receptor function, and the potential for autoimmune-like toxicities. Monitoring biomarkers such as HLA expression and ligand density is crucial for patient selection in these immunotherapies.

Other names
Cancer-cell-associated stress and 'missing-self' ligands recognized by autologous NK/NKT cell receptorsNK cell activating and inhibitory receptorsNKG2D-MICA/B axisKIR-HLA axisMissing-self recognition systemReactome Pathway R-HSA-1236394
02

Mechanism of action

Enhancement of NK cell-mediated tumor lysis by blocking inhibitory checkpoints (KIR, NKG2A) or activating through stress-ligand recognition (NKG2D).

03

Biological functions

Immune responseSignal transductionCell-mediated cytotoxicityApoptosis
04

Disease associations

CancerInfectionAutoimmune disease
05

Safety considerations

Autoimmune toxicitiesCytokine release syndromeTumor escape via ligand shedding
06

Interacting drugs

Monalizumab

4 more in the full profile.

07

Biomarkers

MHC Class I expressionMICA/B surface levelsKIR/NKG2A receptor density

Beyond the preview

Go deeper on Natural killer cell receptor system (NKG2D and KIR) (NKRs).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Natural killer cell receptor system (NKG2D and KIR) (NKRs).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call